SO-010

Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors

Authors

 

GarraldaE 1
FiedlerW 2
MatosI 3
RollingC 4
KebenkoM 4
KlinghammerK 5
ConteG 5
RaspagliesiF 5
HabelB 5
BaumeisterH 5
OchsenreitherS 5
ZurloA 6
Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Barcelona, Spain

University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, Germany Medical Oncology Department, Vall d’Hebron Hospital, Barcelona, Spain University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, Germany, Mologen AG, Berlin, Germany University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, Germany, Mologen AG, Berlin, Germany University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, Germany, Mologen AG, Berlin, Germany

 

Stay in the know.
OncNet Newsletter